# US 2020/0002422 A1 · Method of preventing graft versus host disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0002422 A1
- Document ID: US20200002422A1
- Status: Published application
- Kind: A1
- Application number: 16/084,383
- Filed: 2017-03-13
- Published: 2020-01-02
- Earliest claimed: 2016-03-14
- Assignees: Millennium Pharmaceuticals, Inc.
- Applicants: Millennium Pharmaceuticals, Inc.
- Inventors: Jessica A. SACHS; John E. FORD
- Web page: https://patentgrep.com/patent/US20200002422A1

## CPC

- C07K 16/2839: {against the integrin superfamily}
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for preventing GvHD in a human patient, comprising administering to a patient suffering from GvHD or at risk for GvHD, a humanized antibody having binding specificity for human α4β7 integrin, wherein the human patient has or is going to have an allogeneic stem cell transplantation, and wherein the dosing regimen prevents, improves or eliminates GvHD.

## Claims

### Claim 1

A method of preventing graft versus host disease (GvHD), wherein the method comprises the step of:
administering to a human patient undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), a humanized antibody having binding specificity for human α4β7 integrin,
wherein the humanized antibody is administered to the patient according to the following dosing regimen:
a. an initial dose of 75 mg, 300 mg, 450 mg or 600 mg of the humanized antibody as an intravenous infusion the day before allo-HSCT;
b. followed by a second subsequent dose of 75 mg, 300 mg, 450 mg or 600 mg of the humanized antibody as an intravenous infusion at about two weeks after the initial dose;
c. followed by a third subsequent dose of 75 mg, 300 mg, 450 mg or 600 mg of the humanized antibody as an intravenous infusion at about six weeks after the initial dose;
further wherein the humanized antibody comprises an antigen binding region of nonhuman origin and at least a portion of an antibody of human origin, wherein the humanized antibody has binding specificity for the α4β7 complex, wherein the antigen-binding region comprises the CDRs:
Light chain: CDR1 SEQ ID NO:7
CDR2 SEQ ID NO:8 and
CDR3 SEQ ID NO:9; and
Heavy chain: CDR1 SEQ ID NO:4
CDR2 SEQ ID NO:5 and
CDR3 SEQ ID NO:6.

### Claim 2 (depends on 1)

The method of claim 1, wherein the dosing regimen results in Grade II GvHD, Grade I GvHD or no GvHD.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein said preventing results in sustained α4β7-blockade at the time of hematopoietic stem cell infusion.

### Claim 4 (depends on 1, 2)

The method of claim 1, 2, or 3, wherein tacrolimus is co-administered to the human patient.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1 to 4, wherein methotrexate is co-administered to the human patient.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1 to 5, wherein the humanized antibody is administered to the patient over about 30 minutes.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1 to 6, wherein the humanized antibody is reconstituted from a lyophilized formulation.

### Claim 8 (depends on 7)

The method of claim 7, further wherein the humanized antibody is reconstituted to comprise a stable liquid formulation.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1 to 8, wherein the humanized antibody has a heavy chain variable region sequence of amino acids 20 to 140 of SEQ ID NO:1.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1 to 9, wherein the humanized antibody has a light chain variable region sequence of amino acids 20 to 131 of SEQ ID NO:2.

### Claim 11 (depends on 9, 10)

The method of claim 9 or 10, wherein the humanized antibody has a heavy chain comprising amino acids 20 to 470 of SEQ ID NO:1 and a light chain comprising amino acids 20 to 238 of SEQ ID NO:2.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1 to 11, wherein the humanized antibody is vedolizumab.

### Claim 13

A method of treating a patient suffering from cancer or a nonmalignant hematological, immunological disease or autoimmune disease, comprising the steps of:
a. conditioning the immune system of the patient for hematopoietic stem cell transplant,
b. administering a humanized antibody having binding specificity for human α4β7 integrin,
c. waiting at least 12 hours,
d. administering allogeneic hematopoietic stem cells,
e. waiting thirteen days, then administering a second dose of humanized antibody having binding specificity for human α4β7 integrin, and
f. waiting four weeks, then administering a third dose of humanized antibody having binding specificity for human α4β7 integrin.

### Claim 14 (depends on 13)

The method of claim 13, further comprising administering tacrolimus to the patient.

### Claim 15 (depends on 13, 14)

The method of claim 13 or 14, further comprising administering methotrexate to the patient.

### Claim 16 (depends on 13, 14, 15)

The method of anyone of claims 13 to 15, wherein the conditioning of the immune system is myeloablative conditioning or reduced intensity conditioning.

### Claim 17 (depends on 13, 14, 15, 16)

The method of anyone of claims 13 to 16, wherein the patient has an adverse event that does not include stage 3 or stage 4 GvHD of the intestine.

### Claim 18 (depends on 13, 14, 15, 16)

The method of anyone of claims 13 to 16, wherein the patient has an adverse event that does not include grade III or grade IV GvHD.

### Claim 19 (depends on 13, 14, 15, 16)

The method of anyone of claims 13 to 16, wherein the patient has leukemia or lymphoma.

### Claim 20 (depends on 13, 14, 15, 16)

The method of anyone of claims 13 to 16, wherein the allogeneic hematopoietic stem cells are from peripheral blood.

### Claim 21 (depends on 13, 14, 15, 16)

The method of anyone of claims 13 to 16, wherein the allogeneic hematopoietic stem cells engraft without further immunosuppressive therapy.

### Claim 22 (depends on 13, 14, 15, 16)

The method of anyone of claims 13 to 16, wherein the humanized antibody comprises an antigen binding region of nonhuman origin and at least a portion of an antibody of human origin, wherein the humanized antibody has binding specificity for the α4β7 complex, wherein the antigen-binding region comprises the CDRs:
Light chain: CDR1 SEQ ID NO:7
CDR2 SEQ ID NO:8 and
CDR3 SEQ ID NO:9; and
Heavy chain: CDR1 SEQ ID NO:4
CDR2 SEQ ID NO:5 and
CDR3 SEQ ID NO:6.

### Claim 23 (depends on 22)

The method of claim 22, wherein the humanized antibody is reconstituted from a lyophilized formulation.

### Claim 24 (depends on 22)

The method of claim 22, wherein the humanized antibody has a heavy chain variable region sequence of amino acids 20 to 140 of SEQ ID NO:1.

### Claim 25 (depends on 22)

The method of claim 22, wherein the humanized antibody has a light chain variable region sequence of amino acids 20 to 131 of SEQ ID NO:2.

### Claim 26 (depends on 22, 23, 24, 25)

The method of any one of claims 22 to 25, wherein the humanized antibody has a heavy chain comprising amino acids 20 to 470 of SEQ ID NO:1 and a light chain comprising amino acids 20 to 238 of SEQ ID NO:2.

### Claim 27 (depends on 22, 23, 24, 25, 26)

The method of any one of claims 22 to 26, wherein the humanized antibody is vedolizumab.

### Claim 28

A method reducing the occurrence of acute graft versus host disease (GvHD), wherein the method comprises the step of:
administering to a human patient undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), a humanized antibody having binding specificity for human α4β7 integrin,
wherein the humanized antibody is administered to the patient according to the following dosing regimen:
a. an initial dose of 75 mg, 300 mg, 450 mg or 600 mg of the humanized antibody as an intravenous infusion the day before allo-HSCT;
b. followed by a second subsequent dose of 300 mg of the humanized antibody as an intravenous infusion at about two weeks after the initial dose;
c. followed by a third subsequent dose of 300 mg of the humanized antibody as an intravenous infusion at about six weeks after the initial dose;
wherein the humanized antibody comprises an antigen binding region of nonhuman origin and at least a portion of an antibody of human origin, wherein the humanized antibody has binding specificity for the α4β7 complex, wherein the antigen-binding region comprises the CDRs:
Light chain: CDR1 SEQ ID NO:7
CDR2 SEQ ID NO:8 and
CDR3 SEQ ID NO:9; and
Heavy chain: CDR1 SEQ ID NO:4
CDR2 SEQ ID NO:5 and
CDR3 SEQ ID NO:6,
thereby reducing the occurrence of GvHD.

### Claim 29 (depends on 28)

The method of claim 28, wherein reducing the occurrence of acute graft versus host disease (GvHD) results in Grade I or Grade II GvHD, per modified Glucksberg criteria, or similar severity of GvHD per other scoring system, or no GvHD.

### Claim 30 (depends on 28)

The method of claim 28, wherein reducing the occurrence of acute GvHD is a 50% reduction in cumulative incidence and severity of Grade II-IV or Grade III-IV acute GvHD at Day 100 as compared to treatment with methotrexate and calcineurin inhibitor alone.

### Claim 31 (depends on 28)

The method of claim 28, wherein reducing the occurrence of acute graft versus host disease (GvHD) is a reduction in 1 year mortality as compared to treatment with methotrexate and calcineurin inhibitor alone.

### Claim 32

A method of suppressing an immune response in a cancer patient, wherein the method comprises the step of:
administering to a human patient undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), a humanized antibody having binding specificity for human α4β7 integrin,
wherein the humanized antibody is administered to the patient according to the following dosing regimen:
a. an initial dose of 75 mg, 300 mg, 450 mg or 600 mg of the humanized antibody as an intravenous infusion the day before allo-HSCT;
b. followed by a second subsequent dose of 300 mg of the humanized antibody as an intravenous infusion at about two weeks after the initial dose;
c. followed by a third subsequent dose of 300 mg of the humanized antibody as an intravenous infusion at about six weeks after the initial dose;
further wherein the humanized antibody comprises an antigen binding region of nonhuman origin and at least a portion of an antibody of human origin, wherein the humanized antibody has binding specificity for the α4β7 complex, wherein the antigen-binding region comprises the CDRs:
Light chain: CDR1 SEQ ID NO:7
CDR2 SEQ ID NO:8 and
CDR3 SEQ ID NO:9; and
Heavy chain: CDR1 SEQ ID NO:4
CDR2 SEQ ID NO:5 and
CDR3 SEQ ID NO:6.

### Claim 33

A method of treating a transplant patient, wherein the transplant patient is a recipient of an infusion of allogeneic hematopoietic cells, comprising administering an anti-α4β7 antagonist.

### Claim 34 (depends on 33)

The method of claim 33, wherein, prior to the infusion, the transplant patient is the recipient of conditioning therapy selected from myeloablative conditioning or reduced intensity conditioning.

### Claim 35 (depends on 33, 34)

The method of claim 33 or 34, wherein the anti-α4β7 antagonist is administered prior to the infusion.

### Claim 36 (depends on 33, 34)

The method of claim 33 or 34, wherein the anti-α4β7 antagonist is administered in multiple doses, with at least one dose prior to the infusion.

### Claim 37 (depends on 33, 34)

The method of claim 33 or 34, wherein the anti-α4β7 antagonist is administered in multiple doses, with the first dose on the same day as the infusion.

### Claim 38 (depends on 33, 34)

The method of claim 33 or 34, wherein the anti-α4β7 antagonist is administered in multiple doses, with the first dose on the next day after the infusion.

### Claim 39 (depends on 33, 34)

The method of claim 33 or 34, wherein the anti-α4β7 antagonist is administered as a single dose the day before, the day of, or the next day after, the infusion.

### Claim 40 (depends on 35, 36)

The method of claim 35 or 36, wherein a dose of anti-α4β7 antagonist is administered between conditioning and the infusion.

### Claim 41 (depends on 33, 34, 35, 36, 37, 38, 39, 40)

The method of anyone of claims 33 to 40, wherein the transplant patient is suffering from cancer.

### Claim 42 (depends on 41)

The method of claim 41, wherein the cancer is a hematological cancer.

### Claim 43 (depends on 42)

The method of claim 42, wherein the hematological cancer is leukemia, lymphoma, myeloma or a myeloproliferative neoplasm.

### Claim 44 (depends on 43)

The method of claim 43, wherein the leukemia is acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).

### Claim 45 (depends on 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 33 to 40, wherein the transplant patient is suffering from a nonmalignant hematological or immune disease.

### Claim 46 (depends on 45)

The method of claim 45, wherein the nonmalignant hematological or immune disease is selected from the group consisting of hemoglobinopathy, bone marrow failure syndrome, and immune disease.

### Claim 47 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of anyone of claims 33 to 46, wherein the anti-α4β7 antagonist is an anti-α4β7 antibody which has binding specificity for the α4β7 integrin complex

### Claim 48 (depends on 46)

The method of claim 46, wherein the anti-α4β7 antibody is a humanized antibody, wherein the antigen-binding region of the humanized antibody comprises the CDRs:
Light chain: CDR1 SEQ ID NO:7
CDR2 SEQ ID NO:8 and
CDR3 SEQ ID NO:9; and
Heavy chain: CDR1 SEQ ID NO:4
CDR2 SEQ ID NO:5 and
CDR3 SEQ ID NO:6.

### Claim 49 (depends on 48)

The method of claim 48, wherein the humanized antibody is reconstituted from a lyophilized formulation.

### Claim 50 (depends on 47, 48)

The method of claim 47 or 48, wherein the humanized antibody is administered intraveneously.

### Claim 51 (depends on 48, 49, 50)

The method of any one of claims 48 to 50, wherein the humanized antibody has a heavy chain variable region sequence of amino acids 20 to 140 of SEQ ID NO:1.

### Claim 52 (depends on 48, 49, 50, 51)

The method of any one of claims 48 to 51, wherein the humanized antibody has a light chain variable region sequence of amino acids 20 to 131 of SEQ ID NO:2.

### Claim 53 (depends on 51, 52)

The method of claim 51 or 52, wherein the humanized antibody has a heavy chain comprising amino acids 20 to 470 of SEQ ID NO:1 and a light chain comprising amino acids 20 to 238 of SEQ ID NO:2.

### Claim 54 (depends on 48, 49, 50, 51, 52, 53)

The method of any one of claims 48 to 53, wherein the humanized antibody is vedolizumab.

### Claim 55 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of anyone of claims 33 to 54, further comprising treating the transplant patient with tacrolimus, tacrolimus and methotrexate or methotrexate.

### Claim 56 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The method of anyone of claims 33 to 55, further comprising detecting engraftment of the allo-HSCs by measuring neutrophil number.

### Claim 57 (depends on 56)

The method of claim 56, further comprising measuring a biomarker selected from the group consisting of interleukin-6 (IL-6), interleukin-17 (IL-17), suppressor of tumorigenicity 2 (ST2), CD8+ cells, CD38+ cells, CD8+ bright effector memory T cells, and CD4+ memory T cells, wherein the amount of the biomarker measured before or within one week after the infusion and the amount of the biomarker measured at a time 20 to 100 days after the infusion is unchanged.

### Claim 58 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The method of anyone of claims 33 to 57, wherein the patient has an adverse event that does not include stage 3 or stage 4 GvHD of the intestine.

### Claim 59 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of anyone of claims 33 to 58, wherein the allogeneic hematopoietic cells are allogeneic hematopoietic stem cells.

### Claim 60 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of anyone of claims 33 to 58, wherein the allogeneic hematopoietic cells are allogeneic leukocytic cells.

### Claim 61 (depends on 60)

The method of claim 60, wherein the allogeneic leukocytic cells are T-lymphocytes.
